Kiniksa Pharmaceuticals Ltd (KNSA) — Capital Reinvestment Ratio
Latest as of March 2026:
0.00x
Kiniksa Pharmaceuticals Ltd (KNSA) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($50.20 Million) in capital expenditures ($161.00K). See KNSA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$50.20 Million
USD
Capital Expenditures
$161.00K
USD
Data as of
Mar 2026
Most recent filing
Kiniksa Pharmaceuticals Ltd Capital Reinvestment Ratio (2022–2025)
This chart tracks Kiniksa Pharmaceuticals Ltd's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Kiniksa Pharmaceuticals Ltd (2022–2025)
Year-by-year Capital Reinvestment Ratio for Kiniksa Pharmaceuticals Ltd from 2022 to 2025. For live market cap and broader valuation context, see Kiniksa Pharmaceuticals Ltd market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $25.69 Million | $277.00K | ▲ +0.0% |
| 2024 | 0.01x | $25.69 Million | $277.00K | ▲ +10.3% |
| 2023 | 0.01x | $13.30 Million | $130.00K | ▼ -45.9% |
| 2022 | 0.02x | $5.81 Million | $105.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow